michael flynn. end the investigation. i m joined noud by ken dilanian with nbc news it, natasha bertrand who covers is the russia probe with the atlantic and jill wine-banks, all three of you, i want to know what you make of these two witnesses being called, comey already and sessions very soon. and then the president. chris, what i think this shows is mueller is accelerating sat ob struskz justice aspect of the probe. the three pillars of this investigation, it looks like the obstruction case is going down the track further and faster than the collusion and money laundering. there s a lot we don t see but the obstruction witnesses we know who they are and what stories they have to tell. it s not a surprise that comey is a key witness. what s surprising to me is it s happening now and seems like it s speeding up. natasha, explain how you see what kind of a case mueller is going to make here with these hot witnesses now. it seems like ken said he s moving more quickly along the
the pet did not survive the flight. and what the airline is now saying tonight. good evening. and it s great to have you with us here on a very busy tuesday night. that massive storm hitting at this hour, but first tonight, the storm swirling inside president trump s cabinet. president trump firing secretary of state rex tillerson, and doing so in a tweet. the president firing tillerson, then calling him several hours later from air force one. the president naming cia director mike pompeo as the new secretary of state. and look at the wall tonight. at the top there, tillerson fired. he was not the only one fired at the state department today. the undersecretary of state, steve goldstein, who tweeted that tillerson did not know the firing was coming, he was then fired, too. in addition to all of the vacancies that already exist at the top of the state department. and so, we begin tonight with abc s chief white house correspondent jonathan karl. reporter: president trump is in cali
Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).